China Regenerative Medicine International Limited (the “Company”), stock code 08158, published its monthly return for January 2026. The Company’s authorized share capital remained unchanged at 5,000,000,000 ordinary shares, each with a par value of HKD0.2, amounting to a total authorized capital of HKD1,000,000,000.

The total number of issued shares also remained the same, with 304,252,480 issued and no treasury shares. The public float continued to meet the prescribed threshold of 25%. According to the filing, no new shares were issued, and no treasury shares were transferred during the reporting period.

Under the Company’s share option scheme approved on 27 June 2025, 30,425,248 shares may be issued upon full exercise of options. However, there were no issuances or exercises of these options in January 2026. No warrants, convertibles, or other share issuance arrangements were noted.

The Company confirmed compliance with all applicable listing rules, laws, and regulations for the period. All pertinent disclosures, including share capital details and public float status, were reported with no changes from the previous month.